With FDA’s Blessing Seres Preps New “Pivotal” Microbiome Drug Trial

Mar 16, 2017, 11:49 by Michael Croft

Xconomy | Seres Therapeutics wants to become the first company to bring to market a drug that targets the microbiome. Its lead drug failed in clinical trials last year, but now the company is launching a new Phase 2 trials.

March 16, 2017 | Seres Therapeutics wants to become the first company to bring to market a drug that targets the microbiome. Its lead drug failed in clinical trials last year, but now the company is launching a new Phase 2 trials. Xconomy